Epiduo 1 mg/g + 25 mg/g gel Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

epiduo 1 mg/g + 25 mg/g gel

galderma international, tour europlaza, 20 avenue andre prothin, la defense 4, la defense cedex, francuska - adapalen benzoilperoksid - gel - 1 mg/g + 25 mg/g - urbroj: 1 g gela sadrži 1 mg adapalena i 25 mg benzoilperoksida

Mirvaso Europska Unija - hrvatski - EMA (European Medicines Agency)

mirvaso

galderma international - brimonidin tartrat - bolesti kože - ostali dermatološki pripravci - mirvaso je indiciran za simptomatsko liječenje eritema grudi rosacea kod odraslih pacijenata.

Aklief 50 mikrograma/g krema Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

aklief 50 mikrograma/g krema

galderma international, tour europlaza, 20 avenue andre prothin, la defense 4, la defense cedex, francuska - trifaroten - krema - urbroj: jedan gram kreme sadrži 50 mikrograma trifarotena

Epiduo 3 mg/g + 25 mg/g gel Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

epiduo 3 mg/g + 25 mg/g gel

galderma international, tour europlaza, 20 avenue andre prothin, la defense 4, la defense cedex, francuska - adapalen benzoilperoksid - gel - urbroj: jedan gram gela sadrži 3 mg adapalena i 25 mg benzoilperoksida

GOLDERM 25% GEL Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

golderm 25% gel

bosnalijek d.o.o., zagreb - prevencija i pomoć pri liječenju neinficiranih, površinskih ozljeda na koži

Azacitidin Pharmascience 25 mg/ml prašak za suspenziju za injekciju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

azacitidin pharmascience 25 mg/ml prašak za suspenziju za injekciju

pharmascience international limited, lampousas, 1, nicosia, cipar - azacitidin - prašak za suspenziju za injekciju - urbroj: jedna bočica s praškom sadrži 100 mg ili 150 mg azacitidina. nakon rekonstitucije 1 ml suspenzije sadrži 25 mg azacitidina.

Imbruvica Europska Unija - hrvatski - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.